In the past ten years, there has been a remarkable achievement in the use of CAR-T cells for the treatment of blood cancers, particularly acute lymphoblastic leukemia (ALL), lymphomas, and plasma cell myeloma (PCM) [3, 4]. However, some critical issues such as relatively low efficacy, ...
Arsenic trioxide is employed as a standalone treatment or combined with other drugs for acute promyelocytic leukemia. Furthermore, notable advancements have been made in utilizing arsenic trioxide to combat solid tumors, such as hepatocellular carcinoma (HCC). The antitumor properties of As2O3 are ...
A brief overview of the research workflow is as follows, Fig.3. Data was obtained from source website (Probio database) and diseases were assigned to each probiotic based on its ICD code. After constructing a two-mode table of probiotics and their associated diseases, a bipartite network with...
of cancer [29,32,33]. Superior expansion and longer persistence were also observed in early clinical trials in patients with leukemia and non-Hodgkin lymphoma (NHL) [34]. However, Ramello et al. found that, compared to third-generation CARs, second-generation CARs can engage additional species...
(WT1) with a human anti-CLEC9A antibody, specifically delivering WT1 to CD141 + DCs. This strategy indicates higher therapeutic efficacy against WT1-expressing cancers such as acute myeloid leukemia (AML) (Fig.5c1–c3) [139]. Additionally, a nanovaccine targeting CD141 + DCs loaded ...
To preliminarily assess the clinical relevance of perillaldehyde, we tested its ability to induce cell death on patient-derived acute myeloid leukemia biopsies, recording a similar mechanism of action and potency compared to HL-60 cells. To round the study off, we tested its selectivity towards ...
leukemia Fig. 4 Molecular mechanisms of cuproptosis. The molecular mechanisms underlying cuproptosis involve several key processes facilitated by copper ions. i. Cu(II) outside the cell are reverted to Cu(I) by a reductase enzyme. This oxidization-reduction form of copper is then transported ...
AST, aspartate aminotransferase; APOA, apolipoprotein A; HDL, high-density lipoprotein cholesterol; LDLD, low-density lipoprotein direct cholesterol; CHOL, total cholesterol; HBA1C, glycosylated hemoglobin; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; CMML, chronic myelomonocytic leukemia. ...
Grafts engineered to overexpress N5A gave rise to multiple leukemia subtypes in recipient mice, including AMKL, other acute myeloid leukemia subtypes/non-AMKL myeloid leukemia (AML-O), B- and T-cell acute lymphoblastic leukemia (B-ALL and T-ALL; Figure 2B; supplemental Tables 2 and 3). ...
ICD: Immunogenic cell death IL-24: Interleukin-24 ILF3: Interleukin enhancer-binding factor 3 JNK: Jun amino-terminal kinases Jurkat: Acute T-cell leukemia KDELR1: KDEL endoplasmic reticulum protein retention receptor 1 LIF: Leukemia inhibitory factor ...